Competition in the pharmaceutical market is heating up to secure myasthenia gravis indication. UCB's new drug was approved in South Korea, and Janssen finished the phase 3 trial, aiming to acquire regulatory approvals worldwide. In South Korea, Handok seeks to enter the market with its acquired new drug. HanAll Biopharma is conducting a Phase 3 trial and investigating the potential of commercialization.

According to industry sources on November 27, UCB's 'Zilbrysq' was approved in South Korea on November 21. Zilbrysq can be used as an add-on to standard therapies, such as cholinesterase inhibitors, steroids, and immune checkpoint inhibitors. This therapy is a complement C5 inhibitor and works by inhibiting